Breadcrumb

Kathy McGraw, Ph.D.

Kathy McGraw, Ph.D.

  • Center for Cancer Research
  • National Cancer Institute

RESEARCH SUMMARY

Kathy McGraw, Ph.D. is a translational scientist with particular interests in the myeloid malignancies,  Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). Her research focuses on delineating the mechanisms by which vast genetic diversity in MDS and AML converges upon pro-inflammatory pathways leading to chronic inflammation that may be therapeutically exploited. She is also Principal Investigator of the Natural History and Biospecimen Acquisition Protocol for Myelodysplastic Syndromes (NCT05350748).

Areas of Expertise

1) myelodysplastic syndromes 2) acute myeloid leukemia 3) myeloid malignancy 4) innate immunity 5) inflammation

Myeloid Malignancies Program

A trans-NIH multidisciplinary network of researchers and clinicians dedicated to improving early detection, diagnosis, prognosis and development of novel therapeutics for myeloid malignancies.

Publications

Selected Key Publications

Non-del(5q) myelodysplastic syndromes–associated loci detected by SNP-array genome-wide association meta-analysis

Kathy L. McGraw, corresponding author Chia-Ho Cheng, Y. Ann Chen, Hsin-An Hou, Björn Nilsson, Giulio Genovese, Thomas Cluzeau, Andrea Pellagatti, Bartlomiej P. Przychodzen, Mar Mallo, Leonor Arenillas, Azim Mohamedali, Lionel Adès, David A. Sallman, Eric Padron, Lubomir Sokol, Chimene Moreilhon, Sophie Raynaud, Hwei-Fang Tien, Jacqueline Boultwood, Benjamin L. Ebert, Francesc Sole, Pierre Fenaux, Ghulam J. Mufti, Jaroslaw P. Maciejewski, Peter A. Kanetsky and Alan F. List
Blood Advances. 22, 2019.
Full-Text Article
[ Journal Article ]

Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin

Alan F List, Zhuoxin Sun, Amit Verma, John M Bennett, Rami S Komrokji, Kathy McGraw, Jaroslaw Maciejewski, Jessica K Altman, Puneet S Cheema, David F Claxton, Selina M Luger, Ryan J Mattison, Timothy R Wassenaar, Andrew S Artz, Charles A Schiffer, Mark R Litzow, Martin S Tallman
JCO. 2021.
Full-Text Article
[ Journal Article ]

Ribosome biogenesis is a downstream effector of the oncogenic U2AF1-S34F mutation

Abdalla Akef, Kathy McGraw, Steven D Cappell, Daniel R Larson
PLoS Biology. 2020.
Full-Text Article
[ Journal Article ]

The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype

Ashley A Basiorka, Kathy L McGraw, Erika A Eksioglu, Xianghong Chen , Joseph Johnson , Ling Zhang, Qing Zhang, Brittany A Irvine, Thomas Cluzeau , David A Sallman, Eric Padron, Rami Komrokji, Lubomir Sokol, Rebecca C Coll, Avril A B Robertson , Matthew A Cooper, John L Cleveland, Luke A O'Neill, Sheng Wei, Alan F List
Blood. 2016.
Full-Text Article
[ Journal Article ]

The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes

K L McGraw 1 , L M Zhang 2 , D E Rollison 3 , A A Basiorka 4 , W Fulp 5 , B Rawal 6 , A Jerez 7 , D L Billingsley 8 , H-Y Lin 5 , S E Kurtin 9 , S Yoder 2 , Y Zhang 5 , K Guinta 7 , M Mallo 10 , F Solé 10 , M J Calasanz 11 , J Cervera 11 , E Such 11 , T González 12 , T J Nevill 13 , T Haferlach 14 , A E Smith 15 , A Kulasekararaj 15 , G Mufti 15 , A Karsan 13 , J P Maciejewski 7 , L Sokol 1 , P K Epling-Burnette 16 , S Wei 16 , A F List 1
Blood Cancer Journal. 2015.
Full-Text Article
[ Journal Article ]